Stryker to Acquire Amplitude Vascular Systems to Expand Intravascular Lithotripsy Technology Portfolio

Precision moves rarely make noise, but when they land, the impact echoes. On April 13, 2026, Stryker signed a definitive agreement to acquire Amplitude Vascular Systems, and if you know anything about peripheral vascular, you know this is less about shopping and more about sharpening steel, because Boston-built, clinically grounded, and engineered with intent, Amplitude Vascular Systems has been working a very specific problem since 2017, where calcified arterial disease stays stubborn, unforgiving, and expensive to ignore, so they did not ignore it and instead built Pulse IVL, a system designed to fracture calcium while respecting the vessel like it actually matters.

Mark Toland, CEO, congratulations, because building in medtech is not for tourists, it is long cycles, clinical scrutiny, and zero room for fiction, where you either show data or you sit down, and early results from the POWER PAD II study, paired with IDE approval, multicenter momentum, and a device aimed squarely at superficial femoral and popliteal arteries, is exactly how attention gets earned without asking for it.

Backed by BioStar Capital and other institutional players, the company moved through first-in-human work, patent milestones, and pivotal study enrollment with a kind of quiet consistency most startups pretend to have, skipping the loud promises and sticking to progress you can measure and outcomes you can defend.

Now Stryker steps in not to experiment but to extend, giving its Peripheral Vascular portfolio a sharper edge with intravascular lithotripsy that actually speaks the language of calcification, where this move is about complementing what exists rather than replacing it, and once regulatory clearance lines up, Pulse IVL becomes another tool physicians can trust when the artery says no and the patient still needs a yes.

The business takeaway sounds simple but plays hard, because picking a problem that hurts, staying in the pocket long enough to understand it better than anyone else, and building something that fits into how the market already works while making it better is exactly what Amplitude Vascular Systems did, choosing necessity over noise every time.

And necessity, when done right, tends to get acquired, especially in a space where clinical validation, capital alignment, and strategic fit have to align with precision, and when those elements lock in, you get moments like this that are not loud or flashy, just precise.